Hi DrillDown, Thanks for your post, like you I agree its good to have something to work from. Its much better than throwing darts at a board.
One thing however With the GBM trial and the complete lack of treatment for this form of cancer I think there may be a chance of accelerated approval if Cohorts 3 & 4 bring about the results we hope in terms of Safety profile and Efficacy. Maybe a shortened Phase 2 trial in early 2023 with approval mid 2023.
This would negate the need for future cap raisers.
Time will tell I guess.
Pete
CHM Price at posting:
15.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)